Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: Pretreatment levels or kinetics during chemotherapy?

Onkologie

Volumn 30, Issue 1-2, 2007, Pages 39-42

  Boeck, S ^a,b   Schulz, C ^a   Stieber, P ^a   Holdenrieder, S ^a   Weckbach, S ^b   Heinemann, V ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Carbohydrate antigen 19 9; Gemcitabine; Pancreatic cancer; Prognostic factor

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; PEMETREXED; TUMOR MARKER;

ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASE REPORT; CAUSE OF DEATH; CONTINUOUS INFUSION; DISEASE COURSE; FEMALE; HUMAN; KINETICS; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PROGNOSIS; SURVIVAL TIME; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CA-19-9 ANTIGEN; DEOXYCYTIDINE; HUMANS; KINETICS; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33846649482     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097764     Document Type: Article

References (19)

1. Bruns C, Diebold J, Heinemann V, Wilkowski R, Wagner A, Schmid R: Karzinome des exokrinen Pankreas und der periampullären Region; in Sendler A (Hrsg): Gastrointestinale Tumoren. Tumorzentrum München, ed 7. München, Zuckschwerdt, 2006, pp 77-99.
2. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
3. van Custem E, van der Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff DD: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-1438.
4. Ueno H, Okada S, Okusaka T, Ikeda M: Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000;59:296-301.
5. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957-972.
6. Koprowski H, Herlyn M, Steplewski Z, Sears HF: Specific antigen in serum of patients with colon carcinoma. Science 1981;212:53-55.
7. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987;47:5501-5503.
8. Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, Katz A, Simon SD, Gansl RC: Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002;32:35-41.
9. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D: CA 19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005;93:740-743.
10. Louvet C, Labinaca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-3516.
11. Ishii H, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, Ishikawa O, Matsuno S, Yokoyama S: CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997;44:279-283.
12. Gogas H, Lofts FJ, Evans TRJ, Daryanani S, Mansi JL: Are serial measurements of CA 19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 1998;77:325-328.
13. Halm U, Schumann T, Schiefeke I, Witzigmann H, Mossner J, Keim V: Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000;82:1013-1016.
14. Stemmler J, Stieber P, Szymala AM, Schalhorn A, Schermuly MM, Wilkowski R, Helmberger T, Lamerz R, Stoffregen C, Niebler K, Garbrecht M, Heinemann V: Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie 2003;26:462-467.
15. Ziske C, Schlie C, Gorschluter M, Glasmacher U, May U, Strehl J, Sauerbruch T, Schmidt-Wolf IG: Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003;89:1413-1417.
16. Sawaki A, Katsurahara M, Okubo K, Mizuno N, Nakamura T, Tajika M, Kawai H, Toyama T, Yamao K: Can decreasing the serum level of CA 19-9 predict the survival benefit of gemcitabine for advanced pancreatic cancer? Proc Am Soc Clin Oncol 2004;22:365s(abstr 4208).
17. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA: Serum CA 19-9 response as a surrogate marker for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005;93:195-199.
18. Heinemann V, Ouietzsch D, Geiseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-3952.
19. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Valetta P, Bajetta E, Schueller J, Bernhard J, Dietrich D, Scheithauer W: Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer: a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc Am Soc Clin Oncol 2005;23:310s(abstr 4010).